Series No. Applicantists The Following, QCE Cont. of Maching by Express Mach QT CFR (3) Express Mac Lebes No. (Cont. of Maching under 37 OFR (8)) Protect of Maching under 37 OFR (8) Protect of Maching un	
Commercial Section (Control of Control of Co	
\$848.833 /	8704 <u> </u>

RECEIVED

JAN 2 7 3004

PAIENTIEFT. PAUNCHAUCIOELLP Atty. Docket No.:

20200/2093D

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Kreutzer, et al.

Serial No.:

10/612.179

Filed: Entitled:

July 2, 2003 METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

Conf. No.:

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.88

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the Unised States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Paper

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 3. information Disclosure Statement;
- 2. Form PTO-1449;
- Copies of Cited References; and
- Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 20200/2093D. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted.

Date:

January N. 2004

Name: Barbara A. Gyure Registration No.: 34.614 Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

Atty. Docket No.:

20200/20931)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Kreutzer, et al.

Serial No.: Filed:

10/612,179

Entitled:

July 2, 2003 METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

Group Art Unit:

1645

Conf. No.:

5239

CERTIFICATE OF MAILING UNDER 37 C.F.R. \$ 1.80

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Coromissioner for Patents, P.O. Box 1450, Alexandria, VA 223 (3-1450).

Brenda M. Woods

DALAGORKALLY/

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- Information Disclosure Statement;
- 2. Form PTO-1449;
- Copies of Cited References; and
- Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 20200/2093D. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted.

Date: January 8, 2004

Name: Barbara A Gyure Registration No.: 34,614 Palmer & Dodge LLP 111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

Atty. Docket No.:

20200/2093D

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Kreutzer, et al.

Serial No.:

10/612,179 July 2, 2003

Filed: Entitled:

METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

Group Art Unit:

1645

Conf. No.:

5239

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.88

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patenta, P.O. Box 1450, Alexandria, VA 22313-1450.

> Brende M. Woods Name of Person Mailing Paper

Signature of Person Marling Paper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 888 1.56, 1.97 AND 1.98

Dear Sin

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A copy of a portion of the cited documents were submitted to the U.S. Patent and Trademark Office in the parent application, U.S. Serial No. 09/889,802. Copies of the documents in the list which were not submitted with the parent application are enclosed for the Examiner's convenience. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: January 8, 2004

Respectfully submitted.

Name: Barbara A. Gyure Registration No.: 34,614 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

USPTO Form 1489 U.S. Department of Commence Factors and Trademark Office INFORMATION DISCLOSURE STATEMENT				Altomey Docket 20200/2093		Scrisi No. 10/612,179		
				Applicants): Kreutzer et al.				
× 2 . 02 . 22 . 23				Piling Date: July 2, 20	Group: 1645			
Ú.S. PATENT DOCÚMENTS								
Examiner Initial	·	Patent No.	Date	Name	Class	Suiviass	Filing Date (if appropriate)	
······································	<u> </u>	2003/0198627 A1	Oct. 23, 2003	Arts, et al.	424	93.21	Aug. 23, 2002	
************	2.	2003/0190635 A1	Oct. 9, 2003	McSwiggen	435	6	Jul. 25, 2002	
***************************************	3.	2003/0180756 A1	Sep. 25, 2003	Shi, et al.	435	6	Nov. 21, 2002	
	-4.	2003/0176671 A1	Sep. 18, 2003	Reed, et al.	536	23.1	Feb. 7, 2002	
••••••••••	5.	2003/0157030 A1	Aug. 21, 2003	Davis, et al.	424	46	Nov. 4, 2002	
	6.	2003/0148341 A1	Aug. 7, 2003	Sim, et al.	435	6	Nov. 5, 2002	
	7.	2003/0143732 A1	Jul. 31, 2003	Fosnaugh, et al.	435	325	Aug. 20, 2002	
•••••	§.	2003/0125281 AT	Jul. 3, 2003	Lewis, et al.	\$14	44	May 28, 2002	
	9,	2003/0108923 A1	Jun. 12, 2003	Tuschi, et al.	435	6	Sep. 26, 2002	
	10.	2002/0086356 A1	Jul. 4, 2002	Tuschi, et al.	435	69.1	Mar. 30, 2001	
	11,	6,423,489 B1	Jul. 23, 2002	Anderson, et al.	435	6	May 30, 1995	
	12.	6,346,398	Feb. 12, 2002	Pavco, et al.			***************************************	
	13.	6,355,415	Mar. 12, 2002	Wagner, et al.				
	14.	6,482,863	Nov. 19, 2002	Ruth, et al.				
	15.	6,183,959	Feb. 6, 2001	Thompson				
	16.	6,225,291	May 1, 2001	Lewin, et al.			***************************************	
	17.	6,245,560	June 12, 2001	Lisziewicz				
	18.	6,245,748	June 12, 2001	Wellstein, et al.				
*****	19.	6,255,071	July 3, 2001	Beach, et al.				
	20.	6,057,156	May 2, 2000	Akhtar , et al.				
	21.	6,071,890	June 6, 2000	Scheole, et al.				
	22.	6,077,705	June 20, 2000	Duane, et al.				
	23.	6,080,851	June 27, 2000	Pachuk, et al.				
~~~~~	24.	6,087,164	July 11, 2000	Hochberg, et al.		***************************************		
	25.	6,087,172	July 11, 2000	Veerapaneni, et al.		***************************************		
	26.	6,099,823	Aug. 8, 2000	Faib			***************************************	

	28.	6,100,444	Aug. 8, 2000	Frelinger, et al.				****
	29.	6,107,094	Aug. 22, 2000	Crooke				
	30.	5,968,737	Nov. 16, 1999	Ali-Osman , et al.				***************************************
	31.	5,985,620	Nov. 16, 1999	Sioud				•••••••
	32.	5,908,779	June 1, 1999	Cormichael, et al.			<u> </u>	***************************************
***************************************	33.	5.898,031	Apr 27, 1999	Crooke	****			~~~~
	34.	5,891,717	Apr. 6, 1999	Newgard, et al.			**********************	***********
	35.	5,866,701	Feb. 2, 1999	Hampel, et al.				************
	36,	5,864,028	Jan: 26, 1999	Sloud	***************		***************************************	
	37.	5,854,067	Dec. 29, 1998	Newgard , et al.	***************************************			***************************************
	38.	5,814,500	Nov. 1998	Diegz				
	39.	5.811,300	Nov. 22, 1998	Sulliyan , ci al.		-	·	~~~~
	40.	5,811,275	Nov. 22, 1998	Wong-Stasi , et al.				
	41.	5,837,510	Nov. 17, 1998	Goldsmith, et al.				
	42.	5,824,319	Oct. 20, 1998	Norris, et al				*************
	43	5,712,257	Jan. 1998	Carter				*************
	44,	5,639,655	June 17, 1997	Thompson, et al.	1			**********
	45:	5,635,385	June 3, 1997	Leopold, et al.	***************************************			*************
	46.	5,616,459	Apr. 1, 1997	Kramer, et al.			***************************************	***************************************
	47,	5,574,142	Nov. 12, 1996	Meyer, Jr., et al.			****************	***************************************
	48.	5,525,468	June 11, 1996	McSwiggen	***************************************			***************************************
	49.	5,496,698	Mar. 5, 1996	Draper, et al.	***************************************		***************************************	***************************************
***************************************	S0.	5.246,921	Sep. 21, 1993	Reddy, et al	<u> </u>		***************************************	
	51.	5,225,347	July 6, 1993	Goldberg, et al.			***************************************	••••••
	52.	5,112,734	May 12, 1992	Kramer, et al.				***************************************
POREIG	<u>N PATE</u>	NT DOCUMENTS				····	***************************************	
Exammer Imitial		Document No.	Publication Date	Country	Class	Sulviass	Transia	tion
					***************************************		YES	NO
	53.	DE 101 00 586 C1	April 11, 2002	Deutschland (Germany)	CI2N	15/11		Х
	54.	WO 03/080807 A2	Oct. 2, 2003	PCT	CIZN		Χ	
***************************************	55.	WO 03/080794 A2	Oct. 2, 2003	PCT	Cl2N		X	

	86.	Ausubel, F. et al. (19			vm., 141)54	1,2044.		
	85.	Asanuma, H. et al., (1999), "Photoregulation der Bildung und Dissoziation eines DNA-Duplexes durch ein-trans-isomerisierung einer Azobenzoleinheit", Angew. Chem., 111:2547-2549.						
	84.	Ambros, V., (2001),	Dicing Up RNAs"	. <i>Šcienc</i> v, 293:811-81	3.			
·····	83.	Agrawai et al., 1995,			ier CRC			
OTHER	<u> DOCUM</u>	ENTS (including Auch	or, Title, Date, Pert	nent Pages, etc.)				
***************************************	82.	WO94/01550	Jan. 20, 1994	PCT			*****	
***********	81.	DE 196 18 797 A1	Oct. 1996	DE			X	
	80.	DE 196 18 797 C2	Nov. 13, 1997	DE.				X
	79.	DE 19631 919 C2	July 1998	DE			X	
~~~	78.	WO 98/53083	Nov. 26, 1998	PCI				
*****************	77.	WO 99/15682	Apr. 1, 1999	PCT				
	76.	WO 99 32619	July 1, 1999	PCT			************	
*********	75.	WO 99/49029	Sept. 30, 1999	PCI				
******	74.	WO99/53050	Oct. 21, 1999	PCT			***************************************	
	73.	WO 99/61631	Dec. 2, 1999	PCT				.,
*******	72.	WO 00/01846	jan. 13, 2000	PCT				.,
**********	71.	WO 00/44914	Aug. 3, 2000	PCT			***************************************	
***************************************	70.	WO 00/44895	Aug. 3, 2000	POT	Cl2N	15711		χ
	69.	WO 00/63364	-Oct. 26, 2000	PCT			***************************************	
**********	68.	WO 00/68374	Nov. 16, 2000	PCT	CI2N	15/11	X	
	67.	WO 01/75164 A2	Oct. 11, 2001	PCI	C12Q	1/68	X	
***************************************	66.	WO 02/26780 A2	Apr. 4, 2002	PCT	C07K	14/00	X	
***************************************	65.	WO 02/44321 A2	Jun. 6, 2002	PCT	CI2N		X	
	64.	WO 02/068635 A2	Sep. 6, 2002	POT	Cl2N	15/11	X	
************	63.	WO 02/068637 A2	Sep. 6, 2002	PCT	C12N	15/11	X	
***********	62.	WO 03/012052 A2	Feb. 13, 2003	PCI	C12N	11,00		
***************************************	61.	WO 03/016572 A1	Feb. 27, 2003	BC1	CI2Q	48/00	X X	
**************	60.	WQ 03/070283 A2	Aug. 28, 2003	PCT	<u>C07K</u> A61K	40 00	X	
***	59,	WO 03/070750 A2	Aug. 28, 2003	PCT	C12Q		<u>X</u>	
**********		WO 03/070969 A2	Anna - a and a great and a second decountry of the second	PCT PCT	CI2		X	
	<u>56.</u> 57.	WO 03/074654 A2 WO 03/070972 A2	Sep. 12, 2003 Aug. 28, 2003	PCT	CIZN		X	

	87.	Azhayeva, E. et al., (1997), "Inhibitory properties of double helix forming circular oligomedectides", Nucl. Acids Res., 25:4954-4961.
	88.	Bahramian et al.; MOLECULAR AND CELLULAR BIOLOGY, Vol. 19:274 - 283, "Transcriptional and Postgranscriptional Silencing of Rodent α1(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene Jan. 1999
	89.	Barwkar, D.A. et'al.; Proc. Natl. Acad. Sci USA, Vol. 95:11047 – 11052, September 1998, Chemistry Biochemistry
~~~~~~~~~~	90.	Bass, B.L., (2000), "Double-Stranded RNA as a Template for Gene Silencing", Cell, 101:235-238.
	91.	Bhan et al., Nucleic Acid Research, 1997; Vol. 25; p. 3310
	92,	Billy, et al. (2001) PNAS 98(25):14428-33
	93.	Borecky et al. (1981-82) Tex Rep Biol Med 41:575-81 Abstract Only
····	94.	Castelli, J. et el., (998), "The 2-5A system in viral infection and apoptosis", Biomed. Pharmaconhur., 52:386-396.
	95.	Cobaleda, C. et al., (2000). "In vivo inhibition by a site-specific entalytic RNA subunit of Roase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment", Blood, 95(3):731-737.
•	96.	Datenbank MEDLINE bei STN: AN 1999091059 MEDLINE; DN 99091059 zu: Usc of dsRNA- mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Konnerdell J.R.; Carthew R.W.; CELL, (1998 Dec. 23) 95(7):1017-1026.
	97.	Downward, J. et al., (1990), "Identification of a nucleotide exchange-promoting activity for p21"", Proc. Natl. Acad. Sci. USA", 87:5998-6002.
	98.	Elbashir, et al. (2001) Nature 411:494-498
***************************************	99.	Fire, 9/99, RNA-triggered gene silencing, Trends Genet, 15: 358-363.
**************	100.	Fire, A., et al., 1991, Production of Antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle, Development 113: 503-514
	101.	Gautschi, O. et al., (2001), "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligomicleotide Against Tumors of Diverse Histologic Origins", Journal of the National Cancer Institute, 93(6):463-471.
•	102.	Gibbs, J.B. et al., (1988), "Purification of ras GTPase activating protein from bovine brain", Proc. Nat. Acad. Sci. USA", 85:3026-5030.
	103.	Grasby, JA et al.; Biochemistry 1995 Mar 28; 34(12):4068 - 76
•	104.	Griffoy, RH et al.: J Med Chem 1996 Dec 20; 39(26):5100-9
*******	105.	Ha, l et al.; Genes Dev 1996 Dec 1;10(23);3041-50
	106.	Hamilton et al.; SCIENCE, Vol. 286:950 - 951, "A Species of Small Annisense RNA in Postiranscriptional Gene Silencing in Plants (Oct. 29, 1999)
	107.	Hammond, S.M. et al., (2000), "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drasophila</i> cells", <i>Nature</i> , 404;293-296.
	108.	Hoke, GD et al.; Nucleic Acids Res 1991 Oct 25; 19(20):5743-8

.

.

*******		
*******	109.	Holen, T. et al., (2002), "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor", Nucleic Acids Research, 30(8):1757-1766.
	110.	Horn, T et al.; Nucleic Acids Research, 1997, Vol. 25, No. 23; 4842 - 4849
<del>~~</del>	- 111.	Hunter, 6/17/99, A touch of elegance with RNAL, Curr Biolo, 9: R440-R442
***********	112.	Iwase, R et al.; Nucleic Acids Symp Ser 1997; (37);203 - 4
	113.	Jacobs, B.L., and Langland, J.O., 1996, When two stands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology 219: 339-349
	114.	Kennerdell et al.; CELL, Vol. 95, S. 1017 1026; "Use of dsRNA-Mediated Genetic Interference to Domonstrate that frizzled and frizzled 2 Act in the Wingless Pathway" Dec 23, 1998
	115.	Klemens, et al.(1999), The 2 Å Structure of helix 6 of the human signal recognition particle RNA Structure 7(11): 1345-1352
	176.	Kreutzer et al. (1999) Gesellechaft für Biochemic und Molekularbiologie \$169
*********	117.	Lee, et al.; CELL, Vol. 88; S. 637 – 646; March 7, 1997; "The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA
•••••	118.	Li st al., Dev. Biology Volume 210, 1999, p. 238 abstract 346
*******	119.	Lin et al.; NATURE, Vol. 402:128 - 129, "Policing rogue genes" Nov. 11, 1999
·····	120.	Lipardi, C. et al., (2001), "RNAi as Random Degradative PCR: siRNA Primers Conven mRNA into dsRNAs that Are Degraded to Generate New siRNAs", Cell, 107:297-307.
viewie	121.	Lipinski, et al. (1997) Adv. Drug Delivery Review 23:3-25
	122.	Lowy, D.R. et al., (1993), "Function and Regulation of RAS", Annu. Rev. Biochem., 62:851-891,
	123.	Ma MY (1993) Biochem. 32(7):1751-8
	124.	Majumdar, A et al.; Nat Genet 1998 Oct; 20(2):212-4
*********	125.	Milhaud et al., Journal of Interferon Research, 1991, vol. 11, 261-265
	126.	Minks, M. A. et al., The Journal of Biological Chemistry (1979), 254, (20):10180 10183
	127.	Montgomery, M., and Fire, 1998, Analysis of a Caenorhabditis elegans twist homolog identifies conserved and divergent aspects of mesodermal patterning, Genes and Development, 12: 2623-2635.
	128.	Monigomery M.K., et al., 1998, RNA as a targét of double-stronded RNA-mediated genetic interference in Caenorhabditis elegan, Proc. Natl. Acad. Sci. 95: 15502-15507.
*******	129,	Montgomery, et al., July 1998, Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression, TIG, Vol. 14, No. 7., pgs. 255-258
***************************************	130.	Misquitta, L. and Paterson, B.M., 1999, Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic comatic muscle formation, Proc. Natl. Acad. Sci. 96: 1451-1456
<b></b>	131.	Neilsen et al. (1997) Chem. Comm. 825-826
^^~~~~	132.	Ngo, H., et al., 1998, Double-stranded RNA induces mRNA degradation in Trypanosoma brucei, Prec Nail. Acad. Sci. 95: 14687-14692.
	133.	Nikiforov, et al. (1992) Nucleic Acids Research 20(6):1209-1214

134.	Pegman, MD et al.: J. Clin Oncol 1998 Aug: 16(8):2659 71
135_	Ravinderjit, et al. (1997) Bioconjugate Chem. 8:370-377
136.	Rosalind C. Lee, et al.; CELL, Vol. 75, 843 – 854, March 12, 1993; "The C. elegans Herochronic Gene lin-4 Encodes Small RNAs with Antisense Complementary to lin-14"
137.	Seydoux, G., et al., 1996, Repression of gone expression in the embryonic germ lineage of C. cleyans. Nature 382: 713-716
138.	Sharp, P.A., (2001), "RNA interference - 2001", Genes & Development, 15:485-490.
139.	Sharp, P.A., 1999, RNAi and double-stranded RNA. Gene and Development 13: 139-141
140.	Sijen, T. et al., (2001), "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing", Cell, 107:465-476.
141.	Strauss; SCIENCE, Vol. 286:886; "Candidate 'Gene Silencers' Found" Oct. 29, 1999
142.	James D. Thompson, 12/99, Shortcuts from gene sequence to function, Nature Biotechnology, vol. 17, pp. 1158-1159
143.	Timmions et al.; NATURE, 395(6705:854); "Specific Interference by Ingested dsRNA" Oct 29, 1998
144.	Tuschi et al. (Dec 1999) Genes and Dev. 13:3191-7
145.	Voinnet, O. and Baulcombe, D. C., Nature (1997), 398:553
146.	Wagner, et al., 2/19/98, Double-stranded RNA poses puzzle, Nature, 391: 744-745
147.	Wargeirus, et al., 1999, Double-stranded RNA induces specific developmental defects in zebrafish embryos, Biochem Biophys Res Com., 263: 156-161.
148.	Waterhouse et al.: PNAS, Vol. 95:13959 - 13964, "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA November, 1998
149.	Wisney, et al. (2000) Nature Cell Biology 2:70-75
150.	Wild, K. et al., (1999), "The 2 Å structure of helix 6 of the human signal recognition particle RNA". Structure, 7(11):1345-1352.
151.	Yang, D. et al., (2000), "Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in <i>Drosophila</i> embryos", Current Biology, 10:1191-1200.
152.	Yang Shi, et al.; GENES & DEVELOPMENT, Vol. 12, (No. 7):943 – 955; "A CBP/p300 homolog specifies multiple differentiation pathways in Caenorhabditis elegans" Apr 1, 1998
153.	Zamore, et al. (2000) Cell 101:25-33
154.	International Search Report of International Application No. PCT/EP02/00151.
MINER	DATE CONSIDERED

SIXAMINEX: Initial direference development or not injection is in conformance with MPHF 8/9. Draw the through effects in conformance and not considered. Include copy of this term while next constraints in Applican.

^{**}Copies of references and provided as the tope of this saturdaging